Compare OCC & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OCC | TLSA |
|---|---|---|
| Founded | 1983 | 2013 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 125.2M | 145.1M |
| IPO Year | 2001 | 2017 |
| Metric | OCC | TLSA |
|---|---|---|
| Price | $9.38 | $0.69 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $7.97 |
| AVG Volume (30 Days) | 101.1K | ★ 537.6K |
| Earning Date | 12-17-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 290.91 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $87,828,590.00 | N/A |
| Revenue This Year | $22.52 | N/A |
| Revenue Next Year | $18.51 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 37.03 | N/A |
| 52 Week Low | $4.02 | $0.57 |
| 52 Week High | $27.98 | $1.90 |
| Indicator | OCC | TLSA |
|---|---|---|
| Relative Strength Index (RSI) | 34.97 | 33.26 |
| Support Level | $9.27 | N/A |
| Resistance Level | $10.56 | $1.21 |
| Average True Range (ATR) | 0.94 | 0.09 |
| MACD | -0.26 | -0.03 |
| Stochastic Oscillator | 27.19 | 23.22 |
Optical Cable Corp manufactures a broad range of fiber optic and copper data communication cabling and connectivity solutions for the enterprise, wireless carrier, and specialty markets. The Company offers high quality products that operate as a system solution or integrate with other components, including fiber, copper, hybrid cabling, cabinets, racks, enclosures, and deployable solutions for enterprise networks, data centers, residential, campus, Passive Optical LAN installations, and customized applications in military, industrial, mining, petrochemical, renewable energy, and broadcast industries. It operates a single reportable segment covering the design, development, manufacture, and marketing of its cabling and connectivity solutions.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's, and Amyotrophic Lateral Sclerosis. The company's mission is to design and deliver next-generation immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's main immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's, and other CNS indications.